Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
138
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab

Satoshi IchikawaDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan; Correspondence[email protected]
,
Noriko FukuharaDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan;
,
Kei SaitoDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan;
,
Hisayuki YokoyamaDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan;
,
Koichi OnoderaDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan;
,
Yasushi OnishiDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan;
,
Ryo IchinohasamaDepartment of Hematopathology, Tohoku University Hospital, Sendai, Japan
&
Hideo HarigaeDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan;
show all
Pages 1504-1507 | Received 10 Sep 2019, Accepted 01 Jan 2020, Published online: 21 Jan 2020

References

  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • Staber PB, Herling M, Bellido M, et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019;134(14):1132–1143.
  • Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120(3):538–551.
  • Al Hamed R, Bazarbachi AH, Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant. 2020;55:25–39.
  • Devonshire V, Phillips R, Wass H, et al. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol. 2018;265(11):2494–2505.
  • Reda G, Maura F, Gritti G, et al. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. Am J Hematol. 2012;87(9):936–937.
  • Langerijt B, Doorduijn JK, Lam KH, et al. EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab. J Neurol. 2011;258(5):944–945.
  • Cooles FA, Jackson GH, Menon G, et al. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology (Oxford). 2011;50(4):810–812.
  • Kluin-Nelemans HC, Coenen JL, Boers JE, et al. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood. 2008;112(4):1039–1041.
  • Ammatuna E, Sarlo C, Ottaviani L, et al. Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(5):857–858.
  • Sohani AR, Ferry JA, Chang PS, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. JCO. 2010;28(5):e69–e72.
  • Alduaij A, Treaba DO, Winer ES. CD30-positive EBV-associated diffuse large B-cell lymphoma occurring after immunosuppressive therapy for T-cell prolymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):64–67.
  • Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13(17):5124–5132.
  • Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. JCEH. 2019;59(2):72–92.
  • Morscio J, Bittoun E, Volders N, et al. Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients. J Hematopathol. 2016;9(3):113–120.
  • Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299–6305.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.